Objective-To compare the concentration of plasma atrial natriuretic peptide in patients with acute myocardial infarction with a healthy population and to determine whether a raised concentration of plasma atrial natriuretic peptide at admission was a predictor of mortality after acute myocardial infarction.
Abstract
Objective-To compare the concentration of plasma atrial natriuretic peptide in patients with acute myocardial infarction with a healthy population and to determine whether a raised concentration of plasma atrial natriuretic peptide at admission was a predictor of mortality after acute myocardial infarction.
Design-Patients with acute myocardial infarction were divided into a group with no congestion (class I) and a group with congestion (class II-IV) according to their highest Killip classification in the first 24 hours after infarction. The concentration of plasma atrial natriuretic peptide was measured at admission. On the basis of the concentration of atrial natriuretic peptide measured in the healthy population, patients were separated into two groups: a group with a high (>200 pg/ml) and a group with a low concentration of atrial natriuretic peptide (<200 pg/ml). The patients were followed for three years.
Patients-55 patients admitted to the coronary care unit within 12 hours of the appearance of symptoms of acute myocardial infarction were compared with 51 healthy individuals.
Main outcome measures-Plasma atrial natriuretic pepetide, Killip class, mortality.
Results-The patients had significantly higher concentrations of atrial natriuretic peptide than the healthy controls. Furthermore, patients with congestion had a significantly higher concentration of atrial natriuretic peptide than the uncongested group of patients. Total mortality was 34 5%. In the group with a low concentration of atrial natriuretic peptide the mortality was only 13-6%, whereas mortality was significantly higher (48'5%) in the group with a high concentration.
Conclusions-The measurement of atrial natriuretic peptide separated the patients into low and high risk groups after acute myocardial infarction. hours of the onset of symptoms, (c) no vasoactive drugs given at admission before the blood samples were taken, (d) serum creatinine concentration <200 imol/l at admission, (e) no history of chronic liver disease, (J) no permanent or temporary pacemaker treatment, (g) no resuscitation before admission, (h) informed consent. Patients were excluded if they did not meet the inclusion criteria. The patients we studied were followed up to determine mortality. The study was approved by the local ethics committee.
Blood samples were collected at admission from a cubital vein into EDTA-coated tubes containing aprotinin 500 IU/ml and kept in an ice bath. The plasma was centrifuged within an hour and then stored at -20°C until analysis. We used a highly specific and reproducible radioimmunoassay from INC, Holland that included plasma extraction before analysis. '6 The kit was tested in our laboratory: intra and inter assay variation was 5% and 10% respectively. Recovery of added atrial natriuretic peptide was 99% (sensitivity, 0-8 pg/tube = 4 pg/ml plasma).
A normal range of atrial natriuretic peptide was established in 51 healthy controls (20 women) (mean age 54-9, range 27-82 years). They were not taking any medication, had no history of chroniic liver or Itea?t disease, and patients died during the follow up period. Table 2 shows the salient clinical characteristics of those who died and those who survived. Figure 2 shows 
Discussion
Atrial natriuretic peptide was higher in the patients (both uncongested and congested) with acute myocardial infarction than in the healthy controls. We found that the concentra- tion of plasma atrial natriuretic peptide immediately after infarction was significantly higher in congested patients than in patients without congestion and that the concentration of atrial natriuretic peptide of both groups was higher than in healthy controls. It seems to be the severity of the left ventricular dysfunction rather than the degree of myocardial ischaemia that determines the concentration of atrial natriuretic peptide. During percutaneous transluminal coronary angioplasty, which always causes ischaemia of a part of the heart muscle, the concentration of atrial natriuretic peptide was higher in patients in whom pulmonary capillary wedge pressure increased whereas it remained normal in patients in whom it did not increase. Furthermore, myocardial ischaemia provoked by dynamic exercise did not in itself increase the concentration of atrial natriuretic peptide in plasma. 20 There was a good correlation between atrial natriuretic peptide and capillary wedge pressure in uncongested patients during dynamic exercise 10 hours after the onset of symptoms of acute myocardial infarction. '3 In a rat model of myocardial infarction neither atrial natriuretic peptide nor the left ventricular end diastolic pressure correlated linearly with infarct size, whereas there was a good linear correlation between atrial natriuretic peptide and left ventricular end diastolic pressure (r = 0-89, p < 0-001) during volume expansion.2' An increased concentration of atrial natriuretic peptide is likely to aggravate congestive heart failure because intravenous administration of atrial natriuretic peptide reduced blood pressure and increased haemoconcentration in healthy individuals.22 Because atrial natriuretic peptide increases transcapillary water shifts by altering vascular permeability, it has been proposed that a high concentration of atrial natriuretic peptide could contribute to pulmonary oedema in left sided myocardial disease and valve disease. This does not seem to be true of chronic heart failure where "acute" atrial natriuretic peptide infusion in several studies was associated with potentially beneficial renal, endocrine, and haemodynamic effects.2324 The vasodilatation and decrease in systemic vascular resistance that have been demonstrated could explain the harmful effect of atrial natriuretic peptide in healthy individuals. We know of no studies of the infusion of atrial natriuretic peptide in patients with acute heart failure.
We found a weak but significant increase in atrial natriuretic peptide with age in our healthy controls. Others, however, found no correlation in 124 been used as a prognostic indicator in chronic heart failure, where in 102 patients those with concentrations above the median concentration of atrial natriuretic peptide had a significantly lower two year survival rate than those with a lower concentration. 28 We found that the Killip classification in the first 24 hours after myocardial infarction was a reliable prognostic indicator. All but four of those who died were in clinical heart failure at this time. This accords with the results of a study by Califfet al, who found that mortality in patients with coronary disease was strongly associated with left ventricular dysfunction. The detection of ventricular arrhythmias during a 24 hour monitoring period gave no further information on the prognosis if the haemodynamic indices were known.29 The methods of assessing left ventricular dysfunction differ from one investigation to another, but in all mortality was associated with the degree of heart failure. A combination of physiological markers such as low left ventricular ejection fraction measured by radionuclide ventriculography, clinical heart failure, and radiological heart failure enhances the reliability of evidence of heart failure as a marker of mortality after acute myocardial infarction.30 Pulmonary capillary wedge pressure measured at admission to the hospital gives a better indication of subsequent mortality than later measurements.3' This might explain why radionuclide ventriculography performed 10 days after infarction in 39 patients with overt pulmonary oedema (Killip class III) was unable to predict the larger mortality in patients with an ejection fraction lower than 0 45 than in patients with a larger ejection fraction. The correlation between ejection fraction and pulmonary capillary wedge pressure was poor because pulmonary capillary wedge pressure in the two groups did not differ.32 The difficulties in estimating heart failure several days after an acute myocardial infarction could be caused by treatment given soon after admission. Compared with other methods of predicting mortality atrial natriuretic peptide has the advantage that the blood sample can be drawn immediately at admission (day or night) by regular staff. The Killip classification is also a simple, reliable and easy way to predict mortality after a myocardial infarction. We found that atrial natriuretic peptide was as good and maybe was better than the Killip classification in predicting outcome. There will always be some inter-observer variability in assigning patients to the Killip classification.
Furthermore we found that when the concentration of atrial natriuretic peptide doubled the relative risk of death increased by a factor 1-7.
We were not able to prove that the measurement of atrial natriuretic peptide can be used to predict congestion, because clinical evidence of congestion developed in too few patients after the first 24 
